Production of nitric oxide (NO) by macrophages is important for the killing of intracellular infectious agents. Interferon (IFN)-gamma and lipopolysaccharide stimulate NO production by transcriptionally up-regulating the inducible NO synthase (iNOS). Macrophages from mice with a targeted disruption of the IFN regulatory factor-1 (IRF-1) gene (IRF-1-/- mice) produced little or no NO and synthesized barely detectable iNOS messenger RNA in response to stimulation. Two adjacent IRF-1 response elements were identified in the iNOS promoter. Infection with Mycobacterium bovis (BCG) was more severe in IRF-1-/- mice than in wild-type mice. Thus, IRF-1 is essential for iNOS activation in murine macrophages.
SummaryExposure of BALB/c mice to mosquitoes infected with irradiated Plasmodium berghei confers protective immunity against subsequent sporozoite challenge. Immunized mice challenged with viable sporozoites develop parasitemia when treated orally with substrate inhibitors of nitric oxide synthase (NOS). This suggests that the production of nitric oxide (NO) prevents the development of exoerythrocytic stages of malaria in liver. Liver tissue from immunized mice expressed maximal levels of mKNA for inducible NOS (iNOS) between 12 and 24 h after challenge with sporozoites. Intraperitoneal injection of neutralizing monoclonal antibody against interferon 3/(IFN-3') or in vivo depletion of CD8 + T cells, but not CD4 + T cells, at the time of challenge blocked expression of iNOS mlLNA and ablated protection in immunized mice. These results show that both CD8 § T cells and IFN-~/are important components in the regulation of iNOS in liver which contributes to the protective response of mice immunized with irradiated malaria sporozoites. IFN-3,, likely provided by malaria-specific CD8 + T cells, induces liver cells, hepatocytes and/or Kupffer cells, to produce NO for the destruction of infected hepatocytes or the parasite within these cells. W ithin minutes after an infected Anopheles mosquito bites the vertebrate host, malaria sporozoites migrate to the liver and invade hepatocytes. There, the parasite matures, and after several days the infected hepatocytes lyse, releasing thousands of merozoites. Once in circulation, the parasite infects erythrocytes causing parasitemia. Prior exposure to irradiated sporozoites confers protective immunity (1, 2). This immunity is directed against liver stage malaria, and does not protect against the blood stage malaria.CD8 + T cells and IFN-3' are required for protective immunity to sporozoite challenge. In vivo depletion of CD8 § T cells or neutralization of IFN-3~ blocks induction of effector activity at the hepatic stage, resulting in parasitaemia (3-5). In vitro studies show that IFN-qr kills parasites by stimulating malaria-infected hepatocytes to produce nitric oxide (NO), and the addition of monomethyl-r-arginine (NGMMLA), a substrate inhibitor of nitric oxide synthase (NOS), to primary cultures of mouse hepatocytes reversed the antiparasitic effects of IFN-'y (6, 7). Human hepatocytes also respond to IFN-3' for NO production (8). As to whether human hepatocytes exhibit antimalaria activity when stimulated to produce NO, remains to be examined.At present, the antimalaria effector mechanism triggered by sporozoites in immunized animals is not fully understood. Presumably malaria-specific CD8 + T cells act directly against infected hepatocytes by recognizing malaria antigen on the cell surface (i.e., induction of CTLs) or malaria-specific lymphocytes release cytokines, such as IFN-3,, upon parasite stimulation, which induces an antimalarial response (3)(4)(5)(9)(10)(11)(12). The relationship between CD8 + T cells, IFN-% and NO-mediated protection in sporozoite-immunized mice was ...
To discover how nitric oxide (NO) synthesis is controlled in different tissues as cells within these tissues combat intracellular pathogens, we examined three distinctively different experimental murine models designed for studying parasite-host interactions: macrophage killing of Leishmania major; nonspecific protection against tularemia (Francisella tularensis) by Mycobacterium bovis (BCG); and specific vaccine-induced protection against hepatic malaria with Plasmodium berghei. Each model parasite and host system provides information on the source and role of NO during infection and the factors that induce or inhibit its production. The in vitro assay for macrophage antimicrobial activity against L. major identified cytokines involved in regulating NO-mediated killing of this intracellular protozoan. L. major induced the production of two competing cytokines in infected macrophages: (1) the parasite activated the gene for tumor necrosis factor (TNF), and production of TNF protein was enhanced by the presence of interferon-gamma (IFN-gamma). TNF then acted as a autocrine signal to amplify IFN-gamma-induced production of NO; and (2) the parasite upregulated production of transforming growth factor-beta (TGF-beta), which blocked IFN-gamma-induced production of NO. Whether parasite-induced TNF (parasite destruction) or TGF-beta (parasite survival) prevailed depended upon the presence and quantity of IFN-gamma at the time of infection. The relationship between NO production in vivo and host resistance to infection was demonstrated with M. bovis (BCG).(ABSTRACT TRUNCATED AT 250 WORDS)
Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Letter to the editor Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency
Nitric oxide (NO) produced by cytokine-treated macrophages and hepatocytes plays a vital role in protective host responses to infectious pathogens. NO inhibits iron-sulfur-dependent enzymes involved in cellular respiration, energy production, and reproduction. Synthesis of L-arginine-derived nitrite (NO2-), the oxidative end product of NO, directly correlates with intracellular killing of Leishmania major, an obligate intracellular protozoan parasite of macrophages: the level of NO2- production is a quantitative index for macrophage activation. The competitive inhibitor of NO synthesis, monomethylarginine (NGMMLA), inhibits both parasite killing and NO2- production. For Leishmania, the parasite itself participates in the regulation of this toxic effector mechanism. This participation is mediated by parasite induction of tumor necrosis factor alpha (TNF alpha), an autocrine factor of macrophages: NO synthesis by interferon-gamma (IFN-gamma)-treated cells can be blocked by monoclonal antibodies to TNF alpha. NO production by IFN gamma-treated hepatocytes is of special interest in malaria infections: sporozoite-infected hepatocytes kill the intracellular malaria parasite after treatment with IFN gamma; this killing is inhibited by NGMMLA.
Francisella tularensis live vaccine strain (LVS) was grown in culture with nonadherent resident, starchelicited, or Proteose Peptone-elicited peritoneal cells. Numbers of bacteria increased 4 logs over the input inoculum in 48 to 72 h. Growth rates were faster in inflammatory cells than in resident cells: generation times for the bacterium were 3 h in inflammatory cells and 6 h in resident macrophages. LVS-infected macrophage cultures treated with lymphokines did not support growth of the bacterium, although lymphokines alone had no inhibitory effects on replication of LVS in culture medium devoid of cells. Removal of gamma interferon (IFN-y) by immunoaffinity precipitation rendered lymphokines ineffective for induction of macrophage anti-LVS activity, and recombinant IFN-y stimulated both resident and inflammatory macrophage populations to inhibit LVS growth in vitro. Inflammatory macrophages were more sensitive to effects of IFN-y: half-maximal activity was achieved at 5 U/ml for inflammatory macrophages and 20 U/mI for resident macrophages. IFN-'y-induced anti-LVS activity correlated with the production of nitrite (NO2-), an oxidative end product of L-arginine-derived nitric oxide (NO). Anti-LVS activity and nitrite production were both completely inhibited by the addition of either the L-arginine analog NG-monomethyl-L-arginine or anti-tumor necrosis factor antibodies to activated macrophage cultures. Thus, macrophages can be activated by IFN-'y to suppress the growth of F. tularensis by generation of toxic levels of NO, and inflammatory macrophages are substantially more sensitive to activation activities of IFN-y for this effector reaction than are more differentiated resident cells.
Tissue factor pathway inhibitor (TFPI) contains three Kunitz-type proteinase inhibitor domains and is a potent inhibitor of tissue factor-mediated coagulation. Here, we report that TFPI inhibits the proliferation of basic fibroblast growth factor-stimulated endothelial cells. A truncated form of TFPI, containing only the first two Kunitz-type proteinase inhibitor domains, has very little antiproliferative activity, suggesting that the carboxyl-terminal region of TFPI is responsible for this activity. Binding studies revealed that full-length TFPI, but not the truncated TFPI molecule, is recognized by the very low density lipoprotein receptor (VLDL receptor) indicating that this receptor is a novel high affinity endothelial cell receptor for TFPI. The antiproliferative activity of TFPI on endothelial cells is inhibited by the receptor-associated protein, a known antagonist of ligand binding by the VLDL receptor, and by anti-VLDL receptor antibodies. These results confirm that the antiproliferative activity of TFPI is mediated by the VLDL receptor and suggest that this receptor-ligand system may be a useful target for the development of new antiangiogenic and antitumor agents.The extrinsic pathway of blood coagulation is initiated when factor VII (fVII) 1 binds to its cellular receptor, tissue factor (TF). The fVIIa⅐TF complex then functions as a potent enzyme, activating factor X which leads to thrombin generation. In addition to initiating coagulation, recent research suggests that fVIIa⅐TF complexes play an important role in angiogenesis (1-3). Zhang et al. (1) correlated TF expression in tumor cells with the ability of the tumors to secrete vascular endothelial growth factor (VEGF) and, in turn, to induce an angiogenic response when implanted in immunodeficient mice. Although TF is not normally expressed on the surface of vascular endothelial cells, in situ hybridization studies have detected TF mRNA in tumor-associated endothelial cells from patients with invasive breast cancer (2). Finally, in a TF-dependent metastasis model, the binding and proteolytic activity of VIIa was shown to be necessary for the initial steps of tumor metastasis (3).The tissue factor pathway is regulated by a potent inhibitor termed tissue factor pathway inhibitor (TFPI). TFPI forms a tight complex with both fXa and fVIIa leading to their inhibition. The TFPI molecule contains three Kunitz-type domains and a basic carboxyl-terminal region. By employing site-directed mutagenesis, Girard et al. (4) demonstrated that the second Kunitz domain is required for efficient binding and inhibition of fXa, and both Kunitz domains 1 and 2 are required for the inhibition of fVIIa/TF activity. Mutation of the predicted inhibitory residues of the third Kunitz domain had no significant effect on either function of TFPI. Rather, this portion of the molecule binds to the cell surfaces by interacting with cell-surface glycosaminoglycans (5). TFPI can also bind to the low density lipoprotein receptor-related protein (LRP) (6) and, in doing so, mediates ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.